{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:06:51Z","timestamp":1793642811097,"version":"4.5.1"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100014630","name":"Ministry of Health of France","doi-asserted-by":"publisher","award":["PHRC-2018"],"award-info":[{"award-number":["PHRC-2018"]}],"id":[{"id":"10.13039\/501100014630","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cytomegalovirus (CMV) affects 0.5%\u20132.0% of all live births and is the main nongenetic cause of congenital sensorineural hearing loss and neurological damage, yet no validated prenatal treatment exists for infected fetuses. Letermovir, a CMV-specific antiviral, is approved for prophylaxis in transplant recipients. This study aimed to quantify maternal-fetal exposure to letermovir following maternal administration, focusing on CMV-target fetal organs, particularly the brain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Seven pregnant women undergoing second-trimester termination of pregnancy for fetal anomalies received oral letermovir (240 or 480\u202fmg once daily) for 3 days. On the day of termination, samples from maternal and fetal blood, placenta, and fetal organs were collected and analyzed. Plasma and tissue drug concentrations were compared to the letermovir half-maximal effective concentration to assess potential antiviral efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Letermovir achieved therapeutic levels in all compartments. Complementary physiologically based pharmacokinetic modeling confirmed adequate fetal exposure across pregnancy stages. No maternal adverse events were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These unique in vivo data provide the first pharmacological rationale supporting letermovir use during pregnancy for congenital CMV therapy.<\/jats:p>\n                    <jats:p>Clinical Trials Registration. NCT04732260.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf619","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T12:28:51Z","timestamp":1765801731000},"page":"848-857","source":"Crossref","is-referenced-by-count":3,"title":["Maternal-Fetal Letermovir Exposure In Vivo and Physiologically Based Pharmacokinetic Modeling: A Rationale for Congenital Cytomegalovirus Therapy"],"prefix":"10.1093","volume":"233","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7510-9364","authenticated-orcid":false,"given":"Valentine","family":"Faure Bardon","sequence":"first","affiliation":[{"name":"Universit\u00e9 Paris-Cit\u00e9, Unit\u00e9 de Recherche Partenariale 7328 Federation for Research into Innovative Explorations and Therapeutics in Utero , Paris ,","place":["France"]},{"name":"Universit\u00e9 Paris-Cit\u00e9, Inserm, Pharmacologie et \u00e9valuations des Th\u00e9rapeutiques Chez L'enfant et la Femme Enceinte , Paris ,","place":["France"]},{"name":"Department of Gynecology and Obstetrics, Sorbonne University, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naim","family":"Bouazza","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Cit\u00e9, Inserm, Pharmacologie et \u00e9valuations des Th\u00e9rapeutiques Chez L'enfant et la Femme Enceinte , Paris ,","place":["France"]},{"name":"Unit\u00e9 de Recherche Clinique Necker Cochin, Assistance Publique\u2013H\u00f4pitaux de Paris , Paris ,","place":["France"]},{"name":"Centre d'investigation Clinique-1419 Inserm, Cochin-Necker , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4359-537X","authenticated-orcid":false,"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[{"name":"Pharmacology Laboratory, Assistance Publique\u2013H\u00f4pitaux de Paris, Hospital Bichat-Claude Bernard, Unit\u00e9 Mixte de Recherche 1137 Inserm, Universit\u00e9 Paris-Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4670-8288","authenticated-orcid":false,"given":"Minh","family":"Patrick Le","sequence":"additional","affiliation":[{"name":"Pharmacology Laboratory, Assistance Publique\u2013H\u00f4pitaux de Paris, Hospital Bichat-Claude Bernard, Unit\u00e9 Mixte de Recherche 1137 Inserm, Universit\u00e9 Paris-Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihem","family":"Benaboud","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Cit\u00e9, Inserm, Pharmacologie et \u00e9valuations des Th\u00e9rapeutiques Chez L'enfant et la Femme Enceinte , Paris ,","place":["France"]},{"name":"Department of Clinical Pharmacology, Cochin Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Universit\u00e9 Paris-Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frantz","family":"Foissac","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Cit\u00e9, Inserm, Pharmacologie et \u00e9valuations des Th\u00e9rapeutiques Chez L'enfant et la Femme Enceinte , Paris ,","place":["France"]},{"name":"Unit\u00e9 de Recherche Clinique Necker Cochin, Assistance Publique\u2013H\u00f4pitaux de Paris , Paris ,","place":["France"]},{"name":"Centre d'investigation Clinique-1419 Inserm, Cochin-Necker , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Lui","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Cit\u00e9, Inserm, Pharmacologie et \u00e9valuations des Th\u00e9rapeutiques Chez L'enfant et la Femme Enceinte , Paris ,","place":["France"]},{"name":"Centre d'investigation Clinique-1419 Inserm, Cochin-Necker , Paris ,","place":["France"]},{"name":"Department of Clinical Pharmacology, Cochin Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Universit\u00e9 Paris-Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3950-7728","authenticated-orcid":false,"given":"L\u00e9o","family":"Froelicher-Bournaud","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Cit\u00e9, Inserm, Pharmacologie et \u00e9valuations des Th\u00e9rapeutiques Chez L'enfant et la Femme Enceinte , Paris ,","place":["France"]},{"name":"Department of Clinical Pharmacology, Cochin Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Universit\u00e9 Paris-Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u00efk","family":"Urien","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Cit\u00e9, Inserm, Pharmacologie et \u00e9valuations des Th\u00e9rapeutiques Chez L'enfant et la Femme Enceinte , Paris ,","place":["France"]},{"name":"Unit\u00e9 de Recherche Clinique Necker Cochin, Assistance Publique\u2013H\u00f4pitaux de Paris , Paris ,","place":["France"]},{"name":"Centre d'investigation Clinique-1419 Inserm, Cochin-Necker , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Bessieres","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Cit\u00e9, Unit\u00e9 de Recherche Partenariale 7328 Federation for Research into Innovative Explorations and Therapeutics in Utero , Paris ,","place":["France"]},{"name":"Fetopathological Unit of Genomic Medicine Department, Necker-Enfants Malades Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Universit\u00e9 Paris-Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Guilleminot","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Cit\u00e9, Unit\u00e9 de Recherche Partenariale 7328 Federation for Research into Innovative Explorations and Therapeutics in Utero , Paris ,","place":["France"]},{"name":"Virology Laboratory, Necker-Enfants Malades Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, University of Paris-Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Bussieres","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Cit\u00e9, Unit\u00e9 de Recherche Partenariale 7328 Federation for Research into Innovative Explorations and Therapeutics in Utero , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Treluyer","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Cit\u00e9, Inserm, Pharmacologie et \u00e9valuations des Th\u00e9rapeutiques Chez L'enfant et la Femme Enceinte , Paris ,","place":["France"]},{"name":"Unit\u00e9 de Recherche Clinique Necker Cochin, Assistance Publique\u2013H\u00f4pitaux de Paris , Paris ,","place":["France"]},{"name":"Centre d'investigation Clinique-1419 Inserm, Cochin-Necker , Paris ,","place":["France"]},{"name":"Department of Clinical Pharmacology, Cochin Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Universit\u00e9 Paris-Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Leruez-Ville","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Cit\u00e9, Unit\u00e9 de Recherche Partenariale 7328 Federation for Research into Innovative Explorations and Therapeutics in Utero , Paris ,","place":["France"]},{"name":"Virology Laboratory, Necker-Enfants Malades Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, University of Paris-Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Ville","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Cit\u00e9, Unit\u00e9 de Recherche Partenariale 7328 Federation for Research into Innovative Explorations and Therapeutics in Utero , Paris ,","place":["France"]},{"name":"Department of Obstetrics, Fetal-Medicine, and Surgery, Necker-Enfants Malades Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, University of Paris-Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"2026051419581612300_jiaf619-B1","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ajog.2020.02.018","article-title":"Cytomegalovirus infection during pregnancy: state of the science","volume":"223","author":"Leruez-Ville","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"2026051419581612300_jiaf619-B2","doi-asserted-by":"crossref","first-page":"380.e1","DOI":"10.1016\/j.ajog.2007.09.052","article-title":"Ultrasound prediction of symptomatic congenital cytomegalovirus infection","volume":"198","author":"Guerra","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"2026051419581612300_jiaf619-B3","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/pd.4118","article-title":"A series of 238 cytomegalovirus primary infections during pregnancy: description and outcome","volume":"33","author":"Picone","year":"2013","journal-title":"Prenat Diagn"},{"key":"2026051419581612300_jiaf619-B4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jcv.2005.09.015","article-title":"Congenital cytomegalovirus infection following first trimester maternal infection: symptoms at birth and outcome","volume":"35","author":"Pass","year":"2006","journal-title":"J Clin Virol"},{"key":"2026051419581612300_jiaf619-B5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/1471-0528.15935","article-title":"Refining the prognosis of fetuses infected with cytomegalovirus in the first trimester of pregnancy by serial prenatal assessment: a single-centre retrospective study","volume":"127","author":"Faure-Bardon","year":"2020","journal-title":"BJOG Int J Obstet Gynaecol"},{"key":"2026051419581612300_jiaf619-B6","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/cid\/ciy1128","article-title":"Sequelae of congenital cytomegalovirus (cCMV) following maternal primary infection are limited to those acquired in the first trimester of pregnancy","volume":"69","author":"Faure-Bardon","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026051419581612300_jiaf619-B7","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.ajog.2020.05.038","article-title":"Timing of primary maternal cytomegalovirus infection and rates of vertical transmission and fetal consequences","volume":"223","author":"Chatzakis","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"2026051419581612300_jiaf619-B8"},{"key":"2026051419581612300_jiaf619-B9","first-page":"299","article-title":"Valacyclovir for prevention and treatment of fetal CMV infection: inclusion in the Law 648\/96 list and launch of the Italian multicentre observational prospective study \u201cMEGAL-ITALI.\u201d","volume":"29","author":"Zammarchi","year":"2021","journal-title":"Infez Med"},{"key":"2026051419581612300_jiaf619-B10","doi-asserted-by":"crossref","first-page":"462.e1","DOI":"10.1016\/j.ajog.2016.04.003","article-title":"In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study","volume":"215","author":"Leruez-Ville","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"2026051419581612300_jiaf619-B11","doi-asserted-by":"crossref","first-page":"100892","DOI":"10.1016\/j.lanepe.2024.100892","article-title":"Consensus recommendation for prenatal, neonatal and postnatal management of congenital cytomegalovirus infection from the European congenital infection initiative (ECCI)","volume":"40","author":"Leruez-Ville","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2026051419581612300_jiaf619-B12","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1093\/jac\/dkad087","article-title":"Assessing the risk of adverse pregnancy outcomes and birth defects reporting in women exposed to ganciclovir or valganciclovir during pregnancy: a pharmacovigilance study","volume":"78","author":"Contejean","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026051419581612300_jiaf619-B13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/tri.12225","article-title":"Preemptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a phase 2a study","volume":"27","author":"Stoelben","year":"2014","journal-title":"Transpl Int"},{"key":"2026051419581612300_jiaf619-B14","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"2026051419581612300_jiaf619-B15","author":"US Food and Drug Administration"},{"key":"2026051419581612300_jiaf619-B16","doi-asserted-by":"crossref","first-page":"e0232140","DOI":"10.1371\/journal.pone.0232140","article-title":"Placental transfer of letermovir and maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection","volume":"15","author":"Bardon","year":"2020","journal-title":"PLoS One"},{"key":"2026051419581612300_jiaf619-B17","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.121.000711","article-title":"Prediction of maternal and fetoplacental concentrations of cefazolin, cefuroxime, and amoxicillin during pregnancy using bottom-up physiologically based pharmacokinetic models","volume":"50","author":"Abduljalil","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"2026051419581612300_jiaf619-B18","doi-asserted-by":"crossref","first-page":"105471","DOI":"10.1016\/j.tiv.2022.105471","article-title":"Predicting fetal exposure of crizotinib during pregnancy: combining human ex vivo placenta perfusion data with physiologically-based pharmacokinetic modeling","volume":"85","author":"Roelofsen","year":"2022","journal-title":"Toxicol In Vitro"},{"key":"2026051419581612300_jiaf619-B19","doi-asserted-by":"crossref","first-page":"E419","DOI":"10.1111\/j.1469-0691.2012.03983.x","article-title":"Congenital cytomegalovirus infection: patterns of fetal brain damage","volume":"18","author":"Gabrielli","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2026051419581612300_jiaf619-B20","doi-asserted-by":"crossref","first-page":"342.e1","DOI":"10.1016\/j.ajog.2016.03.052","article-title":"Feasibility of predicting the outcome of fetal infection with cytomegalovirus at the time of prenatal diagnosis","volume":"215","author":"Leruez-Ville","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"2026051419581612300_jiaf619-B21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3390\/microorganisms8020176","article-title":"Adaptive and innate immune cells in fetal human cytomegalovirus-infected brains","volume":"8","author":"Sellier","year":"2020","journal-title":"Microorganisms"},{"key":"2026051419581612300_jiaf619-B22","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41409-024-02209-2","article-title":"Letermovir for cytomegalovirus infection in pediatric patients undergoing allogenic hematopoietic stem cell transplantation: a real-life study by the Infectious Diseases Working Group of Italian Association of Pediatric Hematology-Oncology (AIEOP)","volume":"59","author":"Galaverna","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"2026051419581612300_jiaf619-B23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40272-022-00547-6","article-title":"Letermovir for prophylaxis and pre-emptive therapy of cytomegalovirus infection in paediatric allogeneic haematopoietic cell transplant patients","volume":"25","author":"K\u00f6rholz","year":"2023","journal-title":"Pediatr Drugs"},{"key":"2026051419581612300_jiaf619-B24","doi-asserted-by":"crossref","first-page":"e13687","DOI":"10.1111\/tid.13687","article-title":"Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients","volume":"23","author":"Linder","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"2026051419581612300_jiaf619-B25","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0140-6736(20)31868-7","article-title":"Valaciclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy: a randomised, double-blind, placebo-controlled trial","volume":"396","author":"Shahar-Nissan","year":"2020","journal-title":"Lancet"},{"key":"2026051419581612300_jiaf619-B26","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/uog.23685","article-title":"Secondary prevention of congenital cytomegalovirus infection with valacyclovir following maternal primary infection in early pregnancy","volume":"58","author":"Faure-Bardon","year":"2021","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2026051419581612300_jiaf619-B27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ajog.2023.07.022","article-title":"The effect of valacyclovir on secondary prevention of congenital cytomegalovirus infection, following primary maternal infection acquired periconceptionally or in the first trimester of pregnancy. An individual patient data meta-analysis","volume":"230","author":"Chatzakis","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"2026051419581612300_jiaf619-B28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00430-017-0512-3","article-title":"Intrauterine therapy of cytomegalovirus infection with valganciclovir: review of the literature","volume":"206","author":"Seidel","year":"2017","journal-title":"Med Microbiol Immunol"},{"key":"2026051419581612300_jiaf619-B29","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1093\/jac\/dkae247","article-title":"In utero treatment of congenital cytomegalovirus infection with valganciclovir: an observational study on safety and effectiveness","volume":"79","author":"Bourgon","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026051419581612300_jiaf619-B30","doi-asserted-by":"crossref","first-page":"e01627-20","DOI":"10.1128\/AAC.01627-20","article-title":"Investigational antiviral therapy models for the prevention and treatment of congenital cytomegalovirus infection during pregnancy","volume":"65","author":"Hamilton","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026051419581612300_jiaf619-B31","author":"Assistance Publique\u2013H\u00f4pitaux de Paris"},{"key":"2026051419581612300_jiaf619-B32","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1111\/ajt.15135","article-title":"Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection","volume":"18","author":"Cherrier","year":"2018","journal-title":"Am J Transplant"},{"key":"2026051419581612300_jiaf619-B33","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s12879-019-4016-1","article-title":"Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient","volume":"19","author":"Jung","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2026051419581612300_jiaf619-B34","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/infdis\/jiz577","article-title":"Letermovir resistance analysis in a clinical trial of cytomegalovirus prophylaxis for hematopoietic stem cell transplant recipients","volume":"221","author":"Douglas","year":"2020","journal-title":"J Infect Dis"},{"key":"2026051419581612300_jiaf619-B35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/jiv352","article-title":"Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK 8228)","volume":"213","author":"Lischka","year":"2016","journal-title":"J Infect Dis"},{"key":"2026051419581612300_jiaf619-B36","doi-asserted-by":"crossref","first-page":"104549","DOI":"10.1016\/j.antiviral.2019.104549","article-title":"In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","volume":"169","author":"Komatsu","year":"2019","journal-title":"Antiviral Res"},{"key":"2026051419581612300_jiaf619-B37","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/QCO.0000000000001065","article-title":"The emergence of letermovir and maribavir drug-resistant mutations: from clinical trials to real-world studies","volume":"37","author":"Zhu","year":"2024","journal-title":"Curr Opin Infect Dis"},{"key":"2026051419581612300_jiaf619-B38","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41409-023-01920-w","article-title":"Cytomegalovirus breakthrough and resistance during letermovir prophylaxis","volume":"58","author":"Perchetti","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"2026051419581612300_jiaf619-B39","doi-asserted-by":"crossref","first-page":"e02337-18","DOI":"10.1128\/AAC.02337-18","article-title":"Use of letermovir as salvage therapy for drug-resistant cytomegalovirus retinitis","volume":"63","author":"Turner","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026051419581612300_jiaf619-B40","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/jpids\/piz050","article-title":"Use of letermovir for salvage therapy for resistant cytomegalovirus in a pediatric hematopoietic stem cell transplant recipient","volume":"9","author":"Kilgore","year":"2020","journal-title":"J Pediatr Infect Dis Soc"},{"issue":"Suppl 1","key":"2026051419581612300_jiaf619-B41","first-page":"1834","article-title":"Maribavir versus valganciclovir for preemptive treatment of cytomegalovirus (CMV) viremia: a randomized, dose-ranging, phase 2 study among hematopoietic stem cell transplant (SCT) and solid organ transplant (SOT) recipients","volume":"3","author":"Maertens","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"2026051419581612300_jiaf619-B42","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.medmal.2018.03.006","article-title":"Maribavir, brincidofovir and letermovir: efficacy and safety of new antiviral drugs for treating cytomegalovirus infections","volume":"48","author":"Frange","year":"2018","journal-title":"Med Mal Infect"},{"key":"2026051419581612300_jiaf619-B43","doi-asserted-by":"crossref","first-page":"496","DOI":"10.2174\/1381612825666190319102812","article-title":"Methodological approaches to evaluate fetal drug exposure","volume":"25","author":"Bouazza","year":"2019","journal-title":"Curr Pharm Des"},{"issue":"Suppl 1","key":"2026051419581612300_jiaf619-B44","first-page":"S94","article-title":"Predicting human fetal drug exposure through maternal-fetal PBPK modeling and in vitro or ex vivo studies","volume":"62","author":"Balhara","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"2026051419581612300_jiaf619-B45","doi-asserted-by":"crossref","first-page":"228.e1","DOI":"10.1016\/j.ajog.2024.05.012","article-title":"Optimization of the betamethasone and dexamethasone dosing regimen during pregnancy: a combined placenta perfusion and pregnancy physiologically based pharmacokinetic modeling approach","volume":"232","author":"Heijden","year":"2024","journal-title":"Am J Obstet Gynecol"},{"key":"2026051419581612300_jiaf619-B46","doi-asserted-by":"crossref","first-page":"1111601","DOI":"10.3389\/fphar.2023.1111601","article-title":"Drug exposure during pregnancy: current understanding and approaches to measure maternal-fetal drug exposure","volume":"14","author":"Hudson","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026051419581612300_jiaf619-B47","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40262-018-0685-y","article-title":"Fetal physiologically based pharmacokinetic models: systems information on the growth and composition of fetal organs","volume":"58","author":"Abduljalil","year":"2019","journal-title":"Clin Pharmacokinet"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf619\/65931741\/jiaf619.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/5\/848\/65931741\/jiaf619.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/5\/848\/65931741\/jiaf619.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:58:30Z","timestamp":1778803110000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/233\/5\/848\/8382231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":47,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,12,17]]},"published-print":{"date-parts":[[2026,5,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf619","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,15]]},"published":{"date-parts":[[2025,12,17]]}}}